In persons with type 1 diabetes and high glycated hemoglobin levels, the benefits of intermittently scanned continuous glucose monitoring with optional alarms for high and low blood glucose levels are ...
As teplizumab opens the door to disease-modifying treatment, researchers say the next era of type 1 diabetes care may depend on protecting beta cells, calming autoimmune attack, and finding patients ...
Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results